Valuation: Zai Lab Limited

Market Cap 2.09B 1.82B 1.7B 1.56B 2.94B 200B 3.01B 20.18B 7.89B 99.16B 7.85B 7.68B 342B P/E 2026 *
-8.3x
P/E 2027 * -9.9x
Enterprise Value 1.6B 1.39B 1.3B 1.2B 2.24B 153B 2.3B 15.42B 6.03B 75.77B 6B 5.87B 261B EV / Sales 2026 *
3.57x
EV / Sales 2027 * 2.89x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 week-8.33%
1 month+5.77%
3 months-11.76%
6 months+13.01%
Current year+10.74%
1 week 16.1
Extreme 16.1
18
1 month 15.6
Extreme 15.6
18.1
3 years 12.8
Extreme 12.8
38.8
5 years 12.8
Extreme 12.8
132
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-2.42%-8.33%-50.60%-42.31% 2.09B
+0.03%+3.00%+24.49%-6.79% 70.73B
+0.28%+2.87%+40.29%+214.73% 54.27B
-4.52%+47.90%+47.90%+47.90% 49.28B
+7.15%+5.51%-52.67%-51.99% 39.94B
+1.76%+2.99%+61.84%-21.11% 30.36B
-2.18%+8.27%+81.16%+101.46% 25.96B
-2.36%-8.67%+60.69%-54.08% 22.14B
-0.22%-2.66%-4.47%+145.08% 19.96B
-2.35%+1.32%+80.71%+142.71% 16.77B
Average +0.21%+2.00%+28.93%+47.56% 36.6B
Weighted average by Cap. +0.23%+2.52%+32.16%+52.65%

Financials

2026 *2027 *
Net sales 448M 390M 364M 335M 629M 42.81B 643M 4.32B 1.69B 21.22B 1.68B 1.64B 73.14B 595M 518M 484M 445M 835M 56.87B 855M 5.73B 2.24B 28.18B 2.23B 2.18B 97.15B
Net income -244M -213M -199M -183M -343M -23.35B -351M -2.35B -920M -11.57B -917M -897M -39.89B -159M -138M -129M -119M -223M -15.19B -228M -1.53B -599M -7.53B -596M -583M -25.96B
Net Debt -493M -430M -402M -369M -693M -47.2B -709M -4.76B -1.86B -23.39B -1.85B -1.81B -80.63B -371M -324M -302M -278M -521M -35.52B -534M -3.58B -1.4B -17.6B -1.39B -1.36B -60.68B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
29/07/26 €16.10 -2.42%
28/07/26 €16.50 +0.61%
27/07/26 €16.40 -3.53%
24/07/26 €17.00 -3.41%
23/07/26 €17.60 -2.22%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
18.31USD
Average target price
33.30USD
Spread / Average Target
+81.89%

Quarterly revenue - Rate of surprise